Jefferies Group reiterated their hold rating on shares of Catalent Inc (NASDAQ:CTLT) in a report released on Thursday morning. They currently have a $28.00 price objective on the stock, up from their previous price objective of $25.00.
Other equities research analysts have also recently issued research reports about the stock. Bank of America Corp. raised shares of Catalent from a neutral rating to a buy rating and set a $28.00 price target on the stock in a research note on Monday, June 20th. They noted that the move was a valuation call. Morgan Stanley reissued a hold rating on shares of Catalent in a research note on Tuesday, August 30th. TheStreet raised shares of Catalent from a sell rating to a hold rating in a research note on Wednesday, August 17th. Zacks Investment Research raised shares of Catalent from a strong sell rating to a hold rating in a research note on Tuesday, July 5th. Finally, Wells Fargo & Co. raised shares of Catalent from a market perform rating to an outperform rating in a research note on Tuesday, June 21st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the stock. Catalent has an average rating of Hold and a consensus target price of $28.67.
Catalent (NASDAQ:CTLT) opened at 25.83 on Thursday. The firm’s 50-day moving average is $25.26 and its 200-day moving average is $25.67. The company has a market cap of $3.22 billion and a PE ratio of 29.02. Catalent has a 52-week low of $18.92 and a 52-week high of $32.24.
Catalent (NASDAQ:CTLT) last released its quarterly earnings results on Monday, August 29th. The company reported $0.52 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.53 by $0.01. The company had revenue of $532.20 million for the quarter. During the same period in the previous year, the company posted $0.61 EPS. The firm’s quarterly revenue was up 4.3% compared to the same quarter last year. On average, equities research analysts anticipate that Catalent will post $1.40 EPS for the current year.
In other Catalent news, major shareholder Blackstone Management Associat sold 17,100,705 shares of the firm’s stock in a transaction on Friday, September 9th. The stock was sold at an average price of $23.58, for a total value of $403,234,623.90. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Pacer Advisors Inc. bought a new position in Catalent during the second quarter valued at approximately $102,000. Barclays PLC raised its position in Catalent by 406.7% in the second quarter. Barclays PLC now owns 5,275 shares of the company’s stock valued at $121,000 after buying an additional 4,234 shares in the last quarter. Emerald Acquisition Ltd. bought a new position in Catalent during the second quarter valued at approximately $123,000. LS Investment Advisors LLC raised its position in Catalent by 85.2% in the second quarter. LS Investment Advisors LLC now owns 7,131 shares of the company’s stock valued at $164,000 after buying an additional 3,280 shares in the last quarter. Finally, Tower Research Capital LLC TRC bought a new position in Catalent during the second quarter valued at approximately $196,000.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with MarketBeat.com's FREE daily email newsletter.